maytansanoid

HER-2-based ADC targeting have been investigated for clinical application in breast cancer treatment [11, 12 ] using trastuzumab emtasime (trastuzumab-DM1; T-DM1), in which trastuzumab is conjugated through a stable thioether bond to the maytansanoid derivative emtasine.